Heparin and Related Drugs for Venous Thromboembolism Prophylaxis: Subcutaneous or Intravenous Continuous Infusion?

Heparin and Related Drugs for Venous Thromboembolism Prophylaxis: Subcutaneous or Intravenous Continuous Infusion? Publisher Pubmed

Izadpanah M¹ ; Khalili H¹ ; Dashtikhavidaki S¹ ; Mohammadi M²

Show Affiliations

1. Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, PO Box 14155/6451, Tehran, 1417614411, Iran
2. Department of Anesthesiology and Critical Care Medicine, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran

Source: Journal of Comparative Effectiveness Research Published:2015

Abstract

In this article, the most evidenced approaches of unfractionated heparin administration for prevention of venous thromboembolism in medical and surgical hospitalized patients will be reviewed. Present data were collected by searching Scopus, PubMed, MEDLINE, Science direct, Clinical trials and Cochrane database systematic reviews. Subcutaneous low doses of unfractionated heparin (10000-15000 IU) in two or three divided doses per day are commonly administrated for venous thromboembolism prevention in different medical and surgical populations. In some populations such as obese surgical and critically ill patients, due to altered pharmacokinetics behavior of unfractionated heparin, continuous intravenous infusion of the low doses of unfractionated heparin has been proposed. © 2015 Future Medicine Ltd.

Related Docs

1. Comparing Safety of Heparin As Continuous Intravenous Infusion and Multiple Subcutaneous Injections, Journal of Comparative Effectiveness Research (2016)

2. Comparing Effects of Different Routes of Heparin Administration on the Serum Biomarkers of Thrombosis, Journal of Comparative Effectiveness Research (2016)

3. Venous Thromboembolism, Practical Cardiology: Principles and Approaches (2022)

4. Comparison of Efficacy and Safety of Two Different Enoxaparin Products in Prevention of Venous Thromboembolism Following Major Obstetric-Gynecological Surgeries: An Open-Label Randomized Clinical Trial, Iranian Journal of Pharmaceutical Research (2019)

Experts (# of related papers)

View all Related Experts

Hossein Khalili (2)

Mostafa Mohammadi (2)

Style	Citing Format
MLA	Izadpanah M, et al.. "Heparin and Related Drugs for Venous Thromboembolism Prophylaxis: Subcutaneous or Intravenous Continuous Infusion?." Journal of Comparative Effectiveness Research, vol. 4, no. 2, 2015, pp. 167-184.
APA	Izadpanah M, Khalili H, Dashtikhavidaki S, Mohammadi M (2015). Heparin and Related Drugs for Venous Thromboembolism Prophylaxis: Subcutaneous or Intravenous Continuous Infusion?. Journal of Comparative Effectiveness Research, 4(2), 167-184.
Chicago	Izadpanah M, Khalili H, Dashtikhavidaki S, Mohammadi M. "Heparin and Related Drugs for Venous Thromboembolism Prophylaxis: Subcutaneous or Intravenous Continuous Infusion?." Journal of Comparative Effectiveness Research 4, no. 2 (2015): 167-184.
Harvard	Izadpanah M et al. (2015) 'Heparin and Related Drugs for Venous Thromboembolism Prophylaxis: Subcutaneous or Intravenous Continuous Infusion?', Journal of Comparative Effectiveness Research, 4(2), pp. 167-184.
Vancouver	Izadpanah M, Khalili H, Dashtikhavidaki S, Mohammadi M. Heparin and Related Drugs for Venous Thromboembolism Prophylaxis: Subcutaneous or Intravenous Continuous Infusion?. Journal of Comparative Effectiveness Research. 2015;4(2):167-184.
BibTex	@article{ author = {Izadpanah M and Khalili H and Dashtikhavidaki S and Mohammadi M}, title = {Heparin and Related Drugs for Venous Thromboembolism Prophylaxis: Subcutaneous or Intravenous Continuous Infusion?}, journal = {Journal of Comparative Effectiveness Research}, volume = {4}, number = {2}, pages = {167-184}, year = {2015} }
RIS	TY - JOUR AU - Izadpanah M AU - Khalili H AU - Dashtikhavidaki S AU - Mohammadi M TI - Heparin and Related Drugs for Venous Thromboembolism Prophylaxis: Subcutaneous or Intravenous Continuous Infusion? JO - Journal of Comparative Effectiveness Research VL - 4 IS - 2 SP - 167 EP - 184 PY - 2015 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract